Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 109

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 109
---
ors, including potential limitations in the scope, breadth, availability, or amount of reimbursement covering ZELSUVMI. Similarly, healthcare settings or patients may determine that the financial burdens of treatment are not acceptable. LNHC’s results may also be negatively impacted if it encounters deficiencies or inefficiencies in its infrastructure or processes. Any of these issues could impair LNHC’s ability to successfully commercialize ZELSUVMI or to generate substantial profit or to meet its expectations with respect to the amount or timing of profit. Any issues or hurdles related to its commercialization efforts may materially adversely affect its business, results of operations, financial condition and prospects. There is no guarantee that LNHC will be successful in its commercialization efforts with respect to ZELSUVMI, or that LNHC will generate significant profit from ZELSUVMI or any product candidate or become profitable.

ZELSUVMI and any of LNHC’s product candidates that receive regulatory approval, may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.

ZELSUVMI and any of LNHC’s product candidates that receive regulatory approval may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If ZELSUVMI**

<div align='center'>60</div>

TABLE OF CONTENTS

for the treatment of molluscum contagiosum or LNHC’s potential product candidates, if approved, do not achieve an adequate level of acceptance, LNHC may not generate sufficient revenue, and it may not become profitable. The degree of market acceptance of ZELSUVMI and LNHC’s product candidates, if approved for commercial sale, will depend on a number of factors, including:

| • | the efficacy, safety and potential advantages compared to alternative treatments; |

| • | LNHC’s ability to offer its products for sale at competitive prices; |

| • | the convenience and ease of administration compared to alternative treatments; |

| • | the willingness of the target patient population to try new treatments and of physicians to prescribe these treatments; |

| • | LNHC’s ability to hire and retain a sales force in the United States; |

| • | the strength of marketing and distribution support; |

| • | the availability of third-party coverage and adequate reimbursement for ZELSUVMI for the treatment of molluscum contagiosum and any product candidates that receive regulatory approval; |

| • | the prevalence and severity of any side effects; and |

| • |